How IL-11 can increase longevity: New anti-ageing research

The dream of eternal youth is a recurring theme throughout human history, and there are always new scientific approaches that bring us a little closer to this dream. A study by researchers from the Medical Research Council Laboratory of Medical Science and Imperial College London is currently causing a stir. These scientists have discovered that switching off a certain protein called interleukin 11 (IL-11) can extend the life expectancy of mice by almost a quarter. Sounds exciting, doesn't it?

In this article, we take a closer look at this groundbreaking research, what exactly IL-11 is, how it affects ageing and what implications these findings could have for us humans. Spoiler: It could be the breakthrough we've all been waiting for. Stay tuned to find out how this study could potentially revolutionise the way we think about ageing.

Basics

To understand why this discovery is so significant, we first need to take a closer look at the protein interleukin 11 (IL-11). IL-11 is a cytokine, a protein that is released by cells and plays a role in signalling in the immune system. Originally, IL-11 was thought to be mostly beneficial as it is involved in processes such as haematopoiesis and tissue repair.

In recent years, however, researchers have found that IL-11 can also have negative effects, particularly in relation to ageing. Studies have shown that the production of IL-11 increases with age and is associated with a number of age-related diseases such as chronic inflammation, fibrosis (hardening and scarring of tissues), metabolic disorders and muscle wasting. These conditions are typical features of ageing and contribute significantly to the health problems experienced by many older people.

A previous study from 2018 has already revealed the pro-fibrotic and pro-inflammatory properties of IL-11, fundamentally changing the previous understanding that IL-11 was anti-fibrotic and anti-inflammatory. The discovery that IL-11 can actually contribute to the deterioration of health in old age was a major turning point in ageing research.

Researchers have found that knocking out the IL-11 gene in mice prevents the negative effects of this protein. The mice lacking IL-11 not only live longer, but also show fewer signs of age-related diseases such as cancer and chronic inflammation. These results have paved the way for the current study, which is investigating whether blocking IL-11 also has similar positive effects in older mice.

By switching off IL-11, scientists hope to significantly improve not only lifespan but also quality of life in old age. The next step is to transfer these findings to humans and see if anti-IL-11 treatments could have similar effects in us. Given that IL-11 is already being tested in clinical trials for other diseases, this could be a realistic goal.

Now that we understand the basics, let's dive deeper into the specific details of the current study and see what results the researchers have achieved.

The Interleukin 11 (IL-11)

Researchers at the Medical Research Council Laboratory of Medical Science and Imperial College London conducted a groundbreaking study to investigate the effects of blocking the protein interleukin 11 (IL-11) on the lifespan of mice. Here are the key points of the study explained simply and clearly:

Experimental design

1. Genetic manipulation:
   • The scientists created mice that had the gene for IL-11 completely removed. These genetically modified mice were thus unable to produce IL-11.
   • The aim was to observe the lifespan and health of these mice in comparison to normal mice.
2. Treatment of older mice:
   • In addition, the researchers treated 75-week-old mice (equivalent to about 55 years of age in humans) with an anti-IL-11 antibody. These antibodies prevent the action of IL-11 in the body.
   • These mice were regularly treated with the anti-IL-11 drug until their natural death.

Results

1. Life extension:
   • An average life extension of over 20% was observed in the genetically modified mice without IL-11.
   • The older mice treated with anti-IL-11 had a 22.4% (males) to 25% (females) longer mean lifespan compared to untreated mice.
2. Health improvements:
   • The treated mice showed fewer signs of cancer and were largely free of common diseases of aging such as fibrosis, chronic inflammation and poor metabolic conditions.
   • A significant reduction in muscle wasting and an improvement in muscle strength were also observed.
3. Side effects:
   • Few side effects were noted, making the treatment appear safe.

Scientific significance

These results are particularly exciting as they indicate that IL-11 plays a key role in the ageing process. By blocking this protein, the researchers were not only able to extend the lifespan, but also significantly improve the quality of life of the mice. The mice showed less cancer, were freer from age-related diseases and had a better physical condition.

Outlook

These promising results could also become relevant for humans in the future. Anti-IL-11 treatments are already being tested in clinical trials for other diseases. There is hope that similar treatments could also extend healthy lifespan in humans. However, further research and clinical trials are needed to confirm the safety and efficacy of these treatments in humans.

Overall, the study shows that knocking out IL-11 could be a potential breakthrough in ageing research. The researchers hope that these findings will pave the way for new anti-ageing therapies and significantly improve the quality of life in old age.

Scientific significance for longevity

The results of this study are significant for several reasons and could revolutionise the way we understand and treat ageing.

Extending healthy lifespan

One of the most impressive findings is the significant extension of lifespan in mice by blocking IL-11. This is not just a mere extension of life, but an improvement in the overall health of the animals. The treated mice had less cancer, suffered less from chronic inflammation and showed better muscle strength. This overall improvement in health means that the mice not only lived longer, but also had a higher quality of life.

Example: Imagine if we could achieve a similar result in humans. This would mean that older people could not only live longer, but also stay healthier and more active. Diseases that are often associated with old age, such as cancer, muscle atrophy and chronic inflammation, could potentially be significantly reduced. This would be a huge step forward for public health and well-being in old age.

Potential for treating age-related diseases

The study shows that IL-11 plays a central role in various age-related diseases. By reducing IL-11, the researchers were able to significantly reduce the frequency and severity of these diseases in mice. This suggests that IL-11 is not only responsible for ageing itself, but also for many of the diseases associated with it.

Example: People suffering from age-related diseases such as fibrosis or chronic inflammation could benefit from a treatment that blocks IL-11. These diseases are often difficult to treat and significantly worsen quality of life. A new therapy that combats these diseases could help many people lead healthier and more fulfilling lives.

Reducing multimorbidity

Multimorbidity, the co-occurrence of multiple chronic diseases, is one of the biggest healthcare challenges of the 21st century. Blocking IL-11 shows the potential to combat multiple age-related diseases simultaneously, significantly improving overall health.

Example: Older people often suffer from multiple chronic diseases simultaneously, such as heart disease, diabetes and arthritis. These conditions typically require complex and often burdensome treatment plans. A therapy that can improve several of these conditions simultaneously would make life much easier for these people and reduce the burden on the healthcare system.

New perspectives for ageing research

The discovery that IL-11 plays such a crucial role in ageing opens up new fields of research and opportunities for future studies. It shows that understanding the molecular and genetic mechanisms of ageing can lead to new and effective treatments.

Example: Further research could show how IL-11 and similar proteins are involved in other ageing processes and how they can be specifically manipulated to slow down ageing. This could lead to a new generation of anti-ageing drugs that target specific molecular targets, making them more effective and with fewer side effects.

Overall, this study shows that the protein IL-11 is a promising target for new anti-ageing therapies. The findings could have a significant impact on healthcare for older people and offer exciting possibilities for future research and treatments. The hope is that these findings could one day lead to not only slowing down ageing, but also significantly improving quality of life in old age.

Potential applications in humans

Blocking IL-11 offers a variety of potential applications in humans that could improve both lifespan and quality of life. Here are some of the most important possibilities:

• Extending lifespan:
  • Anti-IL-11 treatments could help extend the lifespan of people by reducing the negative effects of IL-11 on the body. This could lead to people living longer without suffering from age-related diseases.
• Improving quality of life in old age:
  • Reducing IL-11 could reduce the incidence and severity of age-related diseases such as cancer, fibrosis and chronic inflammation. This would not only extend lifespan, but also significantly improve the quality of life of older people by keeping them healthier and more active.
• Treatment of age-related diseases:
  • Anti-IL-11 therapies could be targeted to treat specific age-related diseases. These include diseases such as muscle wasting (sarcopenia), frailty and metabolic disorders, all of which are associated with elevated IL-11 levels.
• Reducing multimorbidity:
  • One of the biggest challenges in healthcare is the simultaneous treatment of multiple chronic diseases in older people. Anti-IL-11 treatments could help combat several of these diseases simultaneously, improving patients' overall health and well-being.
• Reducing cancer risk:
  • Since blocking IL-11 in mice led to a significant reduction in cancer, there is hope that similar treatments could reduce cancer risk in humans. This would be an important advance as cancer is one of the leading causes of death in old age.
• Supporting organ regeneration:
  • IL-11 is known to hinder the regeneration and healing of organs. Blocking this protein could improve the body's ability to recover from injury and regenerate damaged tissues, which is particularly important in old age.
• Improvement in muscle strength and mass:
  • One of the notable observations in the study was the improvement in muscle strength and mass in the treated mice. This could be particularly helpful for older people who often suffer from muscle wasting, which affects their mobility and independence.
• Development of new anti-ageing drugs:
  • The findings from the IL-11 study could pave the way for the development of new anti-ageing drugs that specifically target the molecular mechanisms of ageing. These drugs could be more effective and safer than current approaches.
• Clinical trials and further development:
  • Anti-IL-11 treatments are already being tested in clinical trials for other diseases. This provides an excellent opportunity to investigate the safety and efficacy of these treatments in the context of ageing and potentially find new indications for these therapies.

These potential applications show how far-reaching the effects of blocking IL-11 could be. Although further research and clinical trials are still needed to confirm safety and efficacy in humans, the results so far offer a promising prospect for future anti-ageing therapies.

Conclusion

The results of the IL-11 blocking study are promising and could revolutionise the way we treat ageing. Future research will focus on translating these findings to humans and confirming the safety and efficacy of anti-IL-11 treatments in clinical trials. In addition, new anti-ageing drugs could be developed that target IL-11 and potentially combat other age-related diseases. The research opens up exciting prospects for significantly improving not only lifespan but also quality of life in old age.

Blocking IL-11 has the potential to be a major breakthrough in ageing research. The study shows that switching off this protein in mice not only extends lifespan, but also improves health in old age. Less cancer, reduced chronic inflammation and improved muscle strength are just some of the positive effects. Although further research is needed, these findings offer hope for new therapeutic approaches that could slow aging and combat age-related diseases.

If you're as intrigued by these findings as we are, stay tuned! Follow our blog for the latest updates in ageing research and share your thoughts in the comments. Want to learn more about anti-ageing therapies? Join our community dedicated to a longer, healthier life. Let's shape the future of longevity together!

Sign up now for free.

_{Sources and studies:}

• _{Original study on blocking IL-11}
• _{Medical Research Council Laboratory of Medical Science and Imperial College London}
• _{Further scientific background on IL-11}